Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Surrozen, Inc. SRZN

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
16.85
Total sells
7.23
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 2 2 7 1 2 — — — — — —
Sell — — — 2 — — — 3 — 1 — —
Insider Ownership
47.78%

Capital & Financial Ratios

Market Cap
199.11
Revenue
11.51
Net Income
(332.13)
Free Cash Flow
(34.98)
Net Debt
(102.04)
Current Ratio
12.14
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
16.77
P/B ratio
0.00
Past 5Y EPS Growth
14.80%
This Y EPS Growth
78.33%
Next Y EPS Growth
48.52%
Next 5Y EPS Growth
51.71%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 36.04 34.57 89.25 102.04
Receivables 2.15 2.54 0.21 5.00
Inventory — — — —
Other — — — —
41.13 38.93 91.56 109.40
2023 2024 2025 Q'26
Payables 0.53 0.31 0.73 1.07
ST’ Debt — — — —
Other — — — —
7.15 7.32 9.93 9.01
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 5.00 5.00 — —
—
’25 0.98 0.98 0.98 0.53
3.48
’24 — — 10.00 0.66
10.66
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (12.49) (7.41) — —
—
’25 (9.28) (6.11) (9.04) (5.81)
(30.24)
’24 (8.75) (5.61) (6.75) 3.48
(17.63)
’23 (14.17) (8.75) (10.13) (7.31)
(40.36)
’22 (18.37) (11.41) (14.15) (0.20)
(44.14)
’21 (10.33) (12.88) (14.06) (11.54)
(48.81)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (12.61) (7.43) — —
—
’25 (9.31) (6.13) (9.06) (5.87)
(30.37)
’24 (8.75) (5.61) (6.75) 3.46
(17.65)
’23 (14.48) (8.83) (10.13) (7.31)
(40.76)
’22 (18.79) (11.44) (14.30) (0.35)
(44.87)
’21 (10.67) (12.94) (14.60) (11.87)
(50.08)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (11.65) (0.41) — —
—
’25 (7.43) 2.55 (8.36) (20.13)
(32.37)
’24 (4.24) (7.99) (0.44) (9.10)
(21.67)
’23 (7.20) (4.65) (5.10) —
(21.33)
’22 (3.45) (6.00) (5.70) (0.45)
(15.59)
’21 (0.02) — (7.65) (5.25)
(33.13)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — ‡‡‡‡‡ 5.15 4.50 6.00 5.90 — — —
Low Price
— — — — — ‡‡‡‡‡ 99.00 20.70 16.19 24.94 — — —
High Price
— — — — ‡‡‡ ‡‡‡‡ 74 42 41 44 — — —
Employees
— — — — ‡‡‡ ‡‡‡ 0.17 0.00 0.26 0.08 — — —
Revenue/Emp
— — — — — — 12.50 — 10.66 3.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — — — ‡‡‡ ‡‡‡ 100.00% — 100.00% 100.00% — — —
Gross Margin
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (36.00) (43.04) (63.56) (242.03) — — —
EBT
— — — — ‡‡‡ ‡‡‡ (288.03%) 0.00% (596.56%) (6,960.77%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ — — ‡‡‡‡‡ ‡‡‡‡‡ (36.00) (43.04) (63.56) (242.03) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.06 1.18 1.44 0.54 — — —
Depreciation
— — — — ‡‡‡ ‡‡‡ 5.40 0.00 3.63 0.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (15.59) (21.33) (21.67) (32.37) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (19.08) (20.00) (6.01) (4.04) — — —
Cash Flow/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (0.31) (0.20) (0.01) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (19.39) (20.20) (6.02) (4.06) — — —
Free CF/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 32.84 18.80 (7.29) (25.11) — — —
Book Value/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.31 2.02 2.93 7.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — 0.00 — 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — 0.00 — 0.00 48.61 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — 0.26 — 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — 0.00 — 0.00 24.08 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
— — — — — — 1.13 — (0.65) (2.76) — — —
EV/FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (44.14) (40.36) (17.63) (30.24) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (0.73) (0.40) (0.03) (0.13) ‡‡‡‡‡ — —
Capex
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (44.87) (40.76) (17.65) (30.37) — — —
FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 71.57 33.98 31.62 81.63 — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 5.60 — — — — — —
Total Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (70.24) (36.04) (34.56) (89.24) — — —
Net Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 76.00 37.94 (21.38) (187.76) — — —
Sh' Equity
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (31.78%) (63.52%) (134.46%) (328.86%) — — —
ROA
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (480.69%) (1,512.29%) 0.00% 0.00% — — —
ROIC
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (38.78%) (75.55%) (767.91%) 231.45% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Surrozen Inc. (SRZN), a clinical-stage biotech pioneering Wnt pathway modulation for regenerative therapies in liver, eye, and metabolic diseases, has ridden the biotech rollercoaster since its 2021 SPAC debut, soaring to $210 before cratering amid sector headwinds like rising rates and funding squeezes. Now trading near late-2024 lows despite a fortified $34.6 million cash pile and sharply reduced burn rates—free cash flow per share improved 70%—the stock shows resilience through positive Phase 1 data for SZN-043 in alcohol-associated hepatitis and upcoming Phase 2 catalysts.

A frenzy of insider buying totaling $24.2 million from March 2025 to February 2026—dwarfing negligible sells—signals deep conviction at 50%+ discounts to peaks, aligning with analyst targets implying 63% average upside. Fundamentals reveal typical pre-commercial lumpiness, with revenue tied to milestones and negative book value, but per-share metrics are brightening amid headcount cuts and efficiency gains.

Projections forecast narrowing losses (EPS improving 55% in 2025), pipeline milestones like SZN-043 readouts in H2 2026, and potential partnerships to extend runway—echoing Viking Therapeutics’ surge on validation. Yet risks like dilution and trial flops loom; this high-beta contrarian play balances insider bets against biotech volatility, warranting a close watch for explosive re-rating potential.

Read full commentary →

Surrozen, Inc. (SRZN) Latest News

News by impact score

Fine-tune

8 Sep

3 , 8:30 AM
Surrozen submits IND application for SZN-8141 to treat diabetic macular edema. IND filing marks regulatory progress for new ophthalmology candidate but remains early-stage development step.

6 Aug

3 , 4:05 PM
Surrozen Inc. released second quarter 2026 financial results and a business update covering operations and pipeline progress. Quarterly results and updates influence near-term financial views and pipeline status for the company.

22 Jul

3 www.marketbeat.com, 4:02 PM
Surrozen highlighted Wnt retina pipeline progress and SZN-8141 IND filing timeline at H.C. Wainwright conference. Pipeline timeline updates at investor conferences can shift short-term biotech sentiment and valuations.

6 May

3 GlobeNewswire, 4:05 PM
Surrozen, Inc. (SRZN) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business update affect key financial performance metrics and investor sentiment.

23 Mar

4 GlobeNewswire, 4:05 PM
Surrozen, Inc. (SRZN) reported fourth quarter and full year 2025 financial results and provided a business update. Financial results and business updates for a clinical-stage biotech like Surrozen signal pipeline progress and cash position, likely driving significant stock volatility and investor reassessment.

15 Feb

4 www.marketbeat.com, 9:10 AM
Surrozen CEO at conference details strategic bet on Wnt-Fzd4 pathway for eye disease and 2026 IND filing plans for SZN-8141. CEO's eye disease strategy and 2026 IND timeline for SZN-8141 mark major pipeline advancement boosting investor sentiment.

8 Dec

3 Simply Wall St., 8:54 AM
Surrozen, Inc. (NASDAQ:SRZN) is under scrutiny regarding its cash management strategies as it navigates its financial future. Investors are hopeful that the company will allocate its resources effectively to support growth and innovation. The focus is on how Surrozen will utilize its available cash to enhance its market position and drive product development, which could significantly influence its trajectory in the competitive biotech landscape. Effective cash management could moderately influence Surrozen's financial performance and competitive positioning.

7 Nov

3 GlobeNewswireBenzingaMoneywiseMoneywiseUSA TODAYMoneywiseYahoo Personal FinanceHR Dive, 4:05 PM
Surrozen, Inc. (SRZN) reported its financial results for the third quarter of 2025, highlighting key developments in its business operations. The company provided updates on its ongoing research and development efforts, including progress on its therapeutic candidates. Financial metrics showed changes in revenue and expenses, reflecting the company's strategic initiatives and market conditions. Surrozen emphasized its commitment to advancing its pipeline and enhancing shareholder value. The financial results and business updates indicate moderate influences on Surrozen's financial performance and strategic direction.

3 Sep

3 GlobeNewswire, 4:15 PM
Surrozen, Inc. (SRZN) will present at an upcoming healthcare investor conference, providing an opportunity for the company to showcase its developments and engage with potential investors. The presentation is expected to highlight Surrozen's innovative approaches in the field of therapeutics, particularly in relation to its proprietary platform and pipeline candidates. The presentation at the investor conference may enhance market sentiment and visibility but is unlikely to lead to immediate significant changes in the company's trajectory.

30 Aug

3 , 8:00 AM
Surrozen, Inc. (NASDAQ:SRZN) has 32% of its shares owned by institutions, while private equity firms also control 32% of the company. This dual ownership structure highlights the significant influence that institutional and private equity investors have on Surrozen's operations and strategic direction. The ownership distribution indicates potential influence on corporate governance and strategic decisions, which may moderately affect the company's performance.

28 Aug

3 GlobeNewswire, 4:15 PM
Surrozen, Inc. (SRZN) will present at an upcoming healthcare investor conference, providing an opportunity for the company to showcase its developments and engage with potential investors. The presentation is expected to highlight Surrozen's innovative approaches in the field of therapeutic development. The conference presentation may enhance investor interest and visibility, but its immediate impact on the company's trajectory is expected to be limited.

8 Aug

3 , 4:05 PM
Surrozen, Inc. (SRZN) reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its business operations. The company provided updates on its ongoing research and development efforts, including progress on its therapeutic candidates. Financial performance showed trends that may influence future strategies and market positioning. The financial results and business updates indicate moderate influence on Surrozen's future performance and market sentiment.

1 Jul

3 Simply Wall St., 8:51 AM
Surrozen, Inc. (NASDAQ:SRZN) has a cash runway of approximately 5.6 years, with US$102 million in cash and a cash burn of US$18 million. Although the company reported only US$12 million in revenue over the last year, it has reduced its cash burn by 48%. Surrozen's cash burn represents about 24% of its US$77 million market capitalization, indicating potential dilution if shares are issued to cover costs. Despite concerns, the overall cash situation suggests a stable path forward, though shareholders should monitor developments closely. The company's cash burn reduction and long cash runway indicate a moderately noticeable influence on its financial performance and growth potential.

14 May

4 , 8:30 AM
Surrozen, Inc. has been granted a patent by the U.S. Patent and Trademark Office for antibody-based molecules that target key receptors in the Wnt pathway. This patent is expected to enhance the company's intellectual property portfolio and may support its ongoing research and development efforts in therapeutic applications related to the Wnt signaling pathway. The patent grant is likely to significantly impact Surrozen's future by strengthening its competitive position and supporting product innovation.

9 May

4 GlobeNewswire, 4:05 PM
Surrozen, Inc. reported its first quarter 2025 financial results, highlighting a strategic pivot to ophthalmology, focusing on treatments for severe eye diseases like age-related macular degeneration and diabetic retinopathy. The company discontinued SZN-043 for alcohol-associated hepatitis due to insufficient clinical benefit. Surrozen plans to advance its lead candidates SZN-8141 and SZN-8143 into clinical studies, with an IND application expected in 2026. The company ended the quarter with $101.6 million in cash, bolstered by a $175 million financing. Despite a net loss of $27 million, Surrozen remains committed to leveraging its Wnt pathway technologies for innovative therapies. The strategic pivot to ophthalmology and advancement of key candidates could significantly alter the company's trajectory and investor sentiment.

4 GlobeNewswire, 8:30 AM
Surrozen presents data on the potential of antibody-based Wnt mimetics in treating cornea endothelial dystrophies and dry eye disease at ARVO Annual Meeting. The presentation of promising data on potential treatments for severe eye diseases could significantly impact Surrozen's future developments and market performance.

31 Mar

4 GlobeNewswire, 4:05 PM
Surrozen, Inc. reported its fourth quarter and full year 2024 financial results, highlighting a focus on ophthalmology programs targeting severe eye diseases. The company completed a financing round of $175 million to support its pipeline, including the development of SZN-413 for retinal diseases. Cash and cash equivalents stood at $34.6 million as of December 31, 2024. Collaboration revenue increased to $10 million due to a milestone with Boehringer Ingelheim. Research and development expenses decreased to $21.1 million, reflecting a restructuring to prioritize clinical programs. The net loss for the year was $63.6 million, up from $43.0 million in 2023. The financing and strategic focus on ophthalmology programs are likely to significantly impact Surrozen's future performance and market positioning.

24 Mar

4 GlobeNewswire, 9:00 AM
Surrozen, Inc. announced an oversubscribed $175 million private placement to focus on its ophthalmology pipeline, particularly for treating serious eye diseases. The financing will support multiple programs through Phase 1 studies. The company will discontinue development of SZN-043 for severe alcohol-associated hepatitis due to insufficient clinical benefit. Surrozen's lead candidates for retinopathies include SZN-8141 and SZN-8143, which target Wnt signaling to potentially improve treatment outcomes for various eye conditions. The private placement involves two tranches, with the first expected to close on March 26, 2025, and the second contingent on FDA clearance for SZN-8141 in 2026. The significant financing and strategic focus on ophthalmology programs could greatly enhance Surrozen's market position and product offerings.

22 Jan

3 , 6:08 AM
Surrozen, Inc. is facing concerns regarding its cash burn rate, which could impact its financial stability and operational capabilities. The company has been spending significantly on research and development, raising questions about its ability to sustain operations without additional funding. Investors are advised to monitor the situation closely as the cash burn could affect future growth prospects and market confidence. High cash burn rates may limit financial flexibility and impact future growth initiatives.

6 Nov

4 GlobeNewswire, 4:30 PM
Surrozen, Inc. to present at two upcoming healthcare investor conferences to discuss targeted therapeutics activating the Wnt pathway for tissue repair and regeneration. The announcement of presenting at key investor conferences indicates significant strategic moves and potential impact on future performance.

3 , 9:00 AM
Surrozen, Inc. (SRZN) provides third quarter 2024 financial results and business update. The financial results and business update may moderately influence key areas such as financial performance and competitive positioning.

4 Nov

4 GlobeNewswire, 8:30 AM
Surrozen, Inc. collaborates with TCGFB, Inc. to develop TGF-β antibodies for Idiopathic Pulmonary Fibrosis. The collaboration has the potential to significantly impact Surrozen's future by developing a novel treatment for a devastating disease.

24 Sep

4 GlobeNewswire, 8:30 AM
Boehringer is advancing the development of SZN-413 for potential clinical testing in retinal diseases, triggering a $10 million milestone payment to Surrozen. The development of SZN-413 for retinal diseases and the milestone payment have the potential to significantly impact Surrozen's future and market performance.

15 Aug

4 Simply Wall St., 6:21 AM
Surrozen (NASDAQ:SRZN) has a cash runway of 14 months with a reduced cash burn rate, but still faces funding distress risk due to high expenditure relative to market value. The article highlights the elevated risk of funding distress and potential impact on Surrozen's future due to high cash burn relative to market value.

12 Aug

4 GlobeNewswire, 4:05 PM
Surrozen, Inc. provided second quarter 2024 financial results and business updates, highlighting progress in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis and publication of studies on Wnt signal activation technologies. Significant progress in clinical trials and development of proprietary technologies expected to have a major impact on future performance and market positioning.

12 Jun

4 GlobeNewswire, 8:30 AM
Surrozen, Inc. publishes study in 'eLife' demonstrating the promise of the proprietary SWEETS platform to enhance Wnt signaling through unique targeted protein degradation technology. The publication of data on the potential to enhance Wnt-signal activation through unique TPD technologies could significantly impact Surrozen's future developments and market performance.

10 Jun

4 GlobeNewswire, 8:30 AM
Surrozen, Inc. presented preliminary results from Phase 1a study of SZN-043 in healthy volunteers and patients with a history of liver cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan. The Phase 1a study results of SZN-043 show potential for significant impact on Surrozen's future with promising safety, target engagement, and Wnt pathway activation in liver regeneration.

4 Jun

4 GlobeNewswire, 8:30 AM
Surrozen, Inc. initiates dosing of first patient in Phase 1b clinical trial of SZN-043 for severe alcohol-associated hepatitis. The initiation of Phase 1b clinical trial for a novel drug targeting severe alcohol-associated hepatitis could have a significant impact on Surrozen's future and market performance.

8 May

4 GlobeNewswire, 4:05 PM
Surrozen provides financial results and updates on SZN-043 Phase 1a trial, ARVO 2024 data, and corporate partnerships. The article highlights significant developments in clinical trials, research programs, and corporate partnerships that could have a major impact on Surrozen's future performance.

3 Apr

4 GlobeNewswire, 8:40 AM
Surrozen's study demonstrates promise of Wnt mimetic antibody in treating pulmonary fibrosis. The study results have the potential to significantly impact Surrozen's future in developing targeted therapeutics for severe lung diseases.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us